Follow our progress.

Milestones in our journey to reinvent genetic testing.

View full list

Press Releases

Invitae Chile, presenting the "Future of Genetic Medicine" in Santiago

Invitae Chile, presenting the "Future of Genetic Medicine" in Santiago

September 20, 2013

SANTIAGO, CHILE – September 20, 2013 - Invitae Corporation, headquartered in San Francisco, California, has announced that Genometrics, a Chilean company located in Santiago, will be the exclusive partner for the Invitae Chile SpA in Chile.  Invitae is a genetic diagnostics company specializing in genetic testing for hereditary diseases in oncology, cardiology, neurology and pediatric medicine.  Invitae previously announced that it will have a fully operational laboratory for the purpose of providing these tests for the Latin American medical community.

The goal of the partnership is to bring the science of genetic medicine to the clinic through an experienced local partner who can facilitate access and education for clinicians to the Invitae offering “The Chilean medical community will now have access to genetic testing to enable patients and physicians to obtain reliable and timely diagnoses for a variety of hereditary diseases” said Lisa Alderson from Invitae. 

“Our partnership with Invitae is an important milestone for genetic medicine in Chile and it will bring significant benefits in terms of making faster and accurate diagnosis more affordable,” said José Luis Valenzuela from Genometrics.

Invitae, in partnership with Genometrics, will host and sponsor a conference in Santiago on Sept. 25th entitled “The Future of Genetic Medicine”.  This conference will serve as an educational program for 200 prominent health care providers from various medical disciplines, and will include speakers Dr. Pilar Carvallo, a recognized geneticist in Chile, and Dr. Pablo Valenzuela from Fundación Ciencia y Vida. 

About Invitae

Specializing in genetic diagnostics for hereditary disorders, Invitae’s mission is to make multi-use genetic testing more accessible and affordable than ever before.

The company is pursuing a strategy over the next several years to aggregate all the world's medical genetic tests (>3,000 known Mendelian conditions) into a single assay at a lower cost than most single gene tests today.

This capability is increasingly enabled by the rapid advancements in DNA sequencing technology and will be advanced by Invitae’s investment in building a database of clinically-relevant genetic information. Invitae hopes to lead the way from an era of genetic scarcity to genetic abundance to significantly improve healthcare worldwide. 

Invitae has raised $47 million from investors, including Thomas, McNerney & PartnersGenomic Health, Inc. (GHDX), Genesys Capital and Randy Scott.  For further information, please visit www.invitae.com.

About Genometrics

Genometrics is a Chilean company, part of the VC Fund EBISA (Empresas de Biotecnología e Innovación S.A.), which has several investments in highly innovative biotechnological products and services in Chile. Genometrics will continue to search for new technologies in the area of genetics to bring to Chile and South América.

Genometrics - Empresas de Biotecnología e Innovación S.A. (EBISA), Av. La Montaña 776, Lampa, Santiago - www.ebisa.cl

Press Contact

Paul Laland
Invitae, Inc.
415.519.6610
pr@invitae.com

Share

Return to press releases